Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Satsuma Pharmaceuticals [STSA]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
Sist oppdatert7 jun 2023 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

0.00% $ 1.100

Live Chart Being Loaded With Signals

Commentary (7 jun 2023 @ 22:00):
Profile picture for Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...

Stats
Dagens volum 1.83M
Gjennomsnittsvolum 1.11M
Markedsverdi 36.47M
EPS $0 ( 2024-03-26 )
Neste inntjeningsdato ( $0 ) 2024-05-09
Last Dividend $0.200 ( 2014-03-28 )
Next Dividend $0 ( N/A )
P/E -0.553
ATR14 $0.0510 (4.64%)
Insider Trading
Date Person Action Amount type
2023-06-08 Ra Capital Management, L.p. Sell 5 914 252 Common Stock
2023-06-08 Ra Capital Management, L.p. Sell 10 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 20 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 30 000 Stock Option (Right to Buy)
2023-06-06 O'neil Thomas P. Sell 13 877 Common Stock, $0.0001 par value
INSIDER POWER
54.69
Last 97 transactions
Buy: 62 291 817 | Sell: 17 994 879

Volum Korrelasjon

Lang: 0.14 (neutral)
Kort: 0.49 (neutral)
Signal:(60.819) Neutral

Satsuma Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
NRBO0.956
DLTH0.937
NXTC0.934
TFFP0.933
TOI0.93
AGLE0.923
PRTK0.923
VIAV0.917
ONCS0.914
SGRP0.914
10 Mest negative korrelasjoner
AGFS-0.944
APEN-0.938
PRDO-0.932
NRIM-0.92
FANH-0.916
VLYPO-0.916
UFPT-0.916
MACK-0.914
TSBK-0.91
AMRB-0.906

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Satsuma Pharmaceuticals Korrelasjon - Valuta/Råvare

The country flag 0.31
( neutral )
The country flag 0.35
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag -0.25
( neutral )
The country flag 0.12
( neutral )

Satsuma Pharmaceuticals Økonomi

Annual 2022
Omsetning: $0
Bruttogevinst: $0 (0.00 %)
EPS: $-2.16
FY 2022
Omsetning: $0
Bruttogevinst: $0 (0.00 %)
EPS: $-2.16
FY 2021
Omsetning: $0.00
Bruttogevinst: $0.00 (0.00 %)
EPS: $-1.623
FY 2020
Omsetning: $0.00
Bruttogevinst: $0.00 (0.00 %)
EPS: $-2.73

Financial Reports:

No articles found.

Satsuma Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

Satsuma Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A
Information
First Dividend $0.150 2012-12-19
Last Dividend $0.200 2014-03-28
Next Dividend $0 N/A
Payout Date 2014-04-15
Next Payout Date N/A
# dividends 7 --
Total Paid Out $1.500 --
Avg. Dividend % Per Year 0.00% --
Score 1.57 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-06-10)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
1.57
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-1.0861.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM1.3391.50010.0010.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM7.440.80010.008.00[1 - 3]
quickRatioTTM7.090.80010.008.00[0.8 - 2.5]
cashRatioTTM3.351.50010.0010.00[0.2 - 2]
debtRatioTTM0.00267-1.5009.96-10.00[0 - 0.6]
interestCoverageTTM107.961.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
freeCashFlowPerShareTTM-1.1172.00-0.559-1.117[0 - 20]
debtEquityRatioTTM0.00308-1.5009.99-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-318.091.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score3.51

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.7731.000-0.1790[1 - 100]
returnOnEquityTTM1.3392.501.15210.00[0.1 - 1.5]
freeCashFlowPerShareTTM-1.1172.00-0.372-1.117[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.005341.500-3.300[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-0.623

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.